<< Press release
The 24th China International In Vitro Diagnostics by CACLP will officially take place 19-21 March 2027 at the Nanjing International Expo Center in Nanjing, Jiangsu Province, China.
The 23rd China International In Vitro Diagnostics by CACLP was successfully held from 21-23 March 2026 in Xiamen, marking another milestone in the event’s continued expansion across China, Southeast Asia and the global market.
In order to promote innovative exchanges and cross-regional cooperation in the global in vitro diagnostics field, the 1st Global IVD Innovation Summit is scheduled to be held in Xiamen on March 22, 2026, during CACLP 2026. Hereby notify the relevant matters as follows:
As artificial intelligence and digital twin technologies rapidly reshape the global healthcare landscape, their integration into clinical practice, laboratory medicine, and biomedical research is opening new frontiers for precision, efficiency, and system-level optimization.
Amid the deepening implementation of the Healthy China 2030 strategy and the rapid convergence of a new global biotechnology revolution, in vitro diagnostics (IVD) has become more critical than ever.
The 11th China Experimental Medicine Conference, themed “Innovation Shaping the Future,” will be held from 21-22 March, 2026, in Xiamen.
As a vital link between innovation and clinical application, IVD distribution enterprises play an indispensable role in ensuring the efficient flow of diagnostic products and services.
Driven by rapid advances in healthcare technology, the IVD industry is entering a new era of innovation and growth. Enlightening Lab Med —— The 9th IVD Youth Entrepreneur Forum will take place on 21 March 2026 at the Xiamen International Expo Center.
As the global in vitro diagnostics (IVD) industry advances toward greater technological sophistication, intelligent automation, and broader clinical applications, the focus of innovation is shifting upstream. Beyond the development of cutting-edge instruments and assays, increasing attention is being placed on the foundational elements that enable performance and reliability—namely critical raw materials, core components, and robust standards systems. Breakthroughs in advanced materials, precision-engineered components, and cross-disciplinary integration are becoming central drivers of sustainable industry growth.
With less than one month remaining before its official opening, the 23rd China International In Vitro Diagnostics by CACLP, together with a series of academic conferences, industry forums, and business meetings, has entered its final countdown stage.
<< Industry news
Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA® BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides a reliable, highly specific diagnostic tool to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell lung cancer (NSCLC). The BAP1 assay is registered as a Class I IVD with the U.S. Food and Drug Administration, has received IVDR approval as a Class C device, and is available globally.
SEKISUI Diagnostics, a global medical diagnostics manufacturer, has announced the launch of a 510(k) cleared rapid test to detect COVID-19 and Flu A&B in professional healthcare settings.
Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver reliable testing with a planned menu of over 100 high-medical-value assays. As the latest offering in Roche’s industry-leading cobas immunoassay systems portfolio, the platform bridges critical operational gaps across health systems by fitting central-laboratory precision into a footprint under one square meter. This enables decentralised sites to manage diverse testing demands directly in-house. With reaction times of 18 minutes or less across more than 90% of Roche immunoassays, local facilities can help reduce diagnostic turnaround times.
Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, and Millennium Health, an accredited specialty laboratory with more than 15 years of experience in drug testing and surveillance, today announced that they have entered into a definitive agreement for Labcorp to acquire Millennium Health.
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel has received Dual 510(k) Clearance and CLIA Waiver* from the U.S. Food and Drug Administration (FDA). This automated, multiplex polymerase chain reaction (PCR) test can simultaneously detect the most common causes of vaginitis in about 20 minutes, directly at the point of care on the BIOFIRE® SPOTFIRE® System, bringing rapid and accurate diagnostics closer to patients.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) and the EQT XI fund (“EQT Private Equity”) today announced an agreement under which Crown NL Bidco B.V. (the “Bidder”) announced its decision to make an all-cash voluntary public takeover offer for the acquisition of all outstanding QIAGEN shares at €46.50 per share (the “Takeover Offer”).
It is a modular urinalysis workflow launched by DIRUI, which can meet the realistic needs of clinical laboratories for automated and high-throughput urine testing.
Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Proscia®, a provider of digital pathology software for clinical and life-sciences customers, in an all-cash transaction valued at $240 million in cash at closing and up to an additional $30 million based on achieving future performance milestones.
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions.
<< Video showcase
Talk with Prof. Leslie Lam at CACLP 2026
Talk with Prof. Vittorio Sambri at CACLP 2026
Talk with Prof. Sergio Bernardini at CACLP 2026
Talk with Prof. Rajiv Erasmus at CACLP 2026
Talk with Prof. Aldo Tomasi at CACLP 2026
Talk with Yinan Tang at CACLP 2026
Talk with Shaoting Zhang at CACLP 2026
Talk with Huai Chen at CACLP 2026
Talk with CHIA Wai Kian at CACLP 2026
Talk with Rahul AGARWAL at CACLP 2026
Talk with Jag Grewal at CACLP 2026
CACLP 2026 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 13th China IVD Industry Development Conference & The 11th China Experimental Medicine Conference
CACLP International Night 2026
The 1st Global IVD Innovation Summit
Go Global: China IVD International Forum 2026
CACLP 2025 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 12th China IVD Industry Development Conference (CIIDC)
The 10th China Experimental Medicine Conference (CEMC)
International Laboratory Medicine and In Vitro Diagnostic Forum
<< Download centre
CACLP 2026 Post-show Report
CACLP 2026 Floor Plan
CACLP 2026 Full Schedule
CACLP 2026 Exhibitor Manual
CACLP 2025 Post-show Report
CACLP 2025 Post-show Press Release
CACLP 2025 Exhibitor Manual
CACLP 2025 Floor Plan
CACLP 2025 Full Schedule
CACLP & CISCE 2024 Draw Global Attention to Innovations and Collaborations in IVD Industry
Copyright © 2026 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
